Clinuvel Pharmaceuticals Limited
CLVLY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.26 | 0.06 | -0.43 |
| FCF Yield | 5.35% | 2.09% | 1.40% | 2.59% |
| EV / EBITDA | 9.73 | 36.09 | 16.11 | 53.61 |
| Quality | ||||
| ROIC | 8.22% | 4.85% | 11.57% | 4.58% |
| Gross Margin | 68.39% | 91.42% | 90.45% | 52.46% |
| Cash Conversion Ratio | 1.26 | 0.93 | 0.43 | 2.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.38% | 34.77% | 37.66% | 36.65% |
| Free Cash Flow Growth | 111.56% | 25.92% | -50.66% | 38.16% |
| Safety | ||||
| Net Debt / EBITDA | -7.40 | -0.95 | -5.25 | -2.61 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.13 | 0.33 | 0.50 | 1.22 |
| Cash Conversion Cycle | 71.70 | 151.68 | 183.53 | 72.15 |